Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

UPM Half-Year Financial Report 2021: Earnings improved rapidly, UPM is fit for future growth

UPM-Kymmene Corporation        Stock Exchange Release (Half-Year Financial Report)        22 July 2021 at 9:30 EEST UPM Half-Year Financial Report 2021:Earnings improved rapidly, UPM is fit for future growth Q2 2021 highlights · Sales increased by 15% to EUR 2,384 million (2,077 million in Q2 2020) · Comparable EBIT increased by 51% to EUR 307 million, 12.9% of sales (203 million, 9.8%) · Operating cash flow increased to EUR 308 million (156 million) · Demand for UPM’s products was strong, and overall, price increases more than offset rising input costs · Following

Ideagen PLC Reports Strong Performance Despite Pandemic

· Acquisitions, Transition to SaaS and Market Growth Contribute to a Successful Financial YearLeading global provider of software for highly regulated industries, Ideagen Plc, has today announced its audited results for the year ended April 2021. The company’s performance has been in line with expectations despite the pandemic, and its strategic acquisition plan, continued transition to a SaaS model and general market growth all contributed to the successful year. The global Governance, Risk and Compliance market is expanding rapidly as regulation increases and companies become more

Directorate Change

22 July 2021 07:00 BST Non-Executive Board appointment AstraZeneca PLC announced today that the Board has appointed Andreas Rummelt as a Non-Executive Director, following the completion yesterday of its acquisition of Alexion Pharmaceuticals, Inc. Dr. Rummelt has been a member of the Board of Alexion since 2010. His effective date of appointment to AstraZeneca's Board is 1 August 2021, the same as that of AstraZeneca's new Executive Director and Chief Financial Officer, Dr. Aradhana Sarin (formerly Executive Vice-President, Chief Financial Officer of Alexion), as previously

First day of trading in Modus Therapeutics shares and warrants on Nasdaq First North Growth Market

STOCKHOLM, SWEDEN - July 22, 2021: First day of trading in Modus Therapeutics AB's (“Modus Therapeutics” or “the Company”) shares and warrants on the Nasdaq First North Growth Market (“First North”) begins today. The Company's shares are traded under the short name “MODTX” and ISIN code SE0015987904, and warrants of series TO 1 are traded under the short name “MODTX TO 1” and ISIN code SE0016075568.Issue of units prior to listing The listing on First North is preceded by an issue of units, the subscription period of which lasted during June / July 2021. The issue of units was

Attendo’s report for the second quarter 2021 – Improvement driven by Finland

Attendo reports improved results for the second quarter of 2021. Organic growth was 5 percent, driven primarily by higher customer inflow in Finland and positive price effects. The pandemic continues to have negative impact on the Scandinavian operations, which however has seen a positive trend in sold beds during the quarter. External evaluations in the quarter has shown that the measures Attendo has taken to protect customers during the pandemic were effective overall.Comments from Martin Tivéus, President and CEO “We are continuing to deliver according to plan on our turnaround

Rottneros interim report January-June 2021

A strong market and stable production improved the resultQ2 2021 compared with (Q2 2020)·SOLD VOLUME was 103,2 (93,1) thousand tons thanks to strong demand.   · PRODUCED VOLUME was at a high level, 109,2 (97,7) thousand tons. In 2020 a maintenance shutdown was held in May.  · NET TURNOVER increased by 16% to 593 (510) MSEK, driven by higher list prices and sales volumes.  · THE LIST PRICE of NBSK pulp in Europe was 40% higher in USD and 22% higher in SEK compared with the second quarter of 2020. The list price has risen from 880 USD to 1 300 USD in the first half of 2021.

Electrolux Professional AB interim report Q2 2021

Second quarter, April – June 2021· Net sales amounted to SEK 1,958m (1,489). Sales increased by 31.5.%. Currency contributed negatively by 7%. Organically sales increased by 38.4%. Last year the quarter was more impacted by the pandemic than this year. · EBITA amounted to SEK 197m (–4), corresponding to a margin of 10.1% (–0.2). · Operating income amounted to SEK 181m (–18), corresponding to a margin of 9.2% (–1.2). · Operating cash flow after investments amounted to SEK 223m (31). · Income for the period amounted to SEK 168m (–28), and earnings per share was SEK 0.58 (–0.10).

Midsona - Interim Report January-June 2021

Improved gross margin in a quarter with challenging comparison figuresApril-June 2021 (second quarter) · Net sales amounted to SEK 903 million (859), but with challenges in organic growth as a result of the previous year’s hoarding effects and increased household consumption. · EBITDA amounted to SEK 78 million (97) before items affecting comparability, corresponding to a margin of 8.6 percent (11.3). · Profit for the period amounted to SEK 24 million (40), corresponding to earnings per share of SEK 0.37 (0.62) before and after dilution. · Free cash flow amounted to SEK -35

Interim report Q2 2021

April – June · Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. · The organic growth[1] during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl[®] from Johnson & Johnson and Flux[®], Decubal[®], Apobase[®], Lactocare[®] from Teva generated growth of +1%. · EBIT (Operating Profit) amounted to MSEK 31.0 (98.6), corresponding to a decline of 69%. · EBITDA[1] amounted to MSEK 180.7 (226.1) corresponding to a decline of 20%. · The gross margin, defined as

Össur hf: Interim report Q2 2021

Announcement no. 15/2021 Interim report Q2 2021 22 July 2021 Jon Sigurdsson, President & CEO, comments: “Sales continued to normalize in our key markets, both in Prosthetics and Bracing and Supports. Sales growth in the second quarter was high as the comparison quarter was the most affected by COVID-19 last year. Restrictions have been lifted in many of our main markets while others are still impacted by measures to control the pandemic. We saw increased profitability, as sales grew, and we will continue to focus on managing cost in line with the sales recovery. As Össur remains

Interim-Report April - June 2021: Increased profit for the first six months but lower sales

January - June · Net sales decreased with -23.0 procent to SEK 64.6 (83.9) million (-18 percent in local currencies). · EBIT amounted to SEK -1.9 (12.1) million. · EBIT margin was -2.9 (14.4) percent. · Profit after tax amounted to SEK -2.9 (10.4) million. · Earnings per share before/after dilution amounted to SEK -0.16 (0.56). · Cash flow from operating activities amounted to SEK 1.1 (-1.6) million. · Cash and cash equivalents at the end of the period amounted to SEK 70.8 (64.8) million. Comments from the CEOIncreased profit for the first half of the year but

Reminder: Invitation to Kongsberg Automotive's Q2 2021 Earnings Call

Kongsberg Automotive ASA will release its second quarter 2021 results on Friday, July 30, 2021, at 07:30 CET. The company will host an earnings conference call for investors, analysts, and media at 09:00 CET on Friday, July 30, which will include a review of the Q2 2021 presentation led by CEO Joerg Buchheim and CFO Frank Heffter. Listeners will have the opportunity to ask questions after the presentation. The Q2 earnings call will be available via audio webcast. Choose the following options to access:Audience web event link: https://globalmeet.webcasts.com/starthere.jsp?ei=1412801&

Resurs Bank Interim Report January-June 2021

“During the second quarter, a number of sustainable partnerships were entered into, digital wallets were launched and our responsible credit lending generated results. The situation in Norway is improving and society is increasingly opening up. Our lending growth amounted to 3 per cent excluding NPL sales during the year and we are capturing market shares.” Nils Carlsson, CEO Resurs Bank AB1 January–30 June 2021* ·Lending to the public rose 1% to SEK 31,148 million, up 1% in constant currencies Excluding NPL sales, growth was 3% · Operating income fell 11% to SEK 1,558 million

Q2 2021 interim report January-June

5 year strategy on track – 31% organic sales growth and 21% Viaplay subscriber growth ·Viaplay paying subscribers up 21% YoY to 3,287k (2,716) with 140k subscribers added QoQ, of which 113k were Nordic subscribers and 27k were international subscribers. 2021 year end international Viaplay subscriber target upgraded from more than 250k to 500k ·31% organic sales growth with reported sales of SEK 3,072m (2,624m including SEK 238m contribution from subsequently deconsolidated Viasat Consumer business) ·Operating income before associated company income (ACI) and items

Betsson AB (publ) interim report April – June 2021

All time high profit driven by stable and scalable business modelQUARTER APRIL – JUNE 2021 · Group revenue was SEK 1,751.6 (1,532.8) million, an increase of 14%. Organic increase of 24%. · Casino revenue decreased by 5%. Sportsbook revenue increased by 125% and the sportsbook margin was 8.5% (6.9%). · Operating income (EBIT) was SEK 383.4 (217.7) million, an increase of 76%, the EBIT margin was 21.9% (14.2%). · Net income was SEK 337.9 (192.9) million, corresponding to SEK 2.54 (1.40) per share. · Operating cash flow was SEK 570.7 (343.9) million. · Active customers

Resurs Holding Interim Report January–June 2021

“During the second quarter, a number of sustainable partnerships were entered into, digital wallets were launched and our responsible credit lending generated results. The situation in Norway is improving and society is increasingly opening up. Our lending growth amounted to 3 per cent excluding NPL sales during the year and we are capturing market shares.” Nils Carlsson, CEO Resurs Holding AB1 April–30 June 2021* · Lending to the public rose 1% to SEK 31,148 million, up 1% in constant currencies. Excluding NPL sales, growth was 3%. · Operating income fell 10% to SEK 840 million ·

EQT AB (publ) Half-year Report 2021

Healthy performance and expanding palette of active ownership strategies “EQT delivered healthy performance during the first six months of 2021 and made good progress in key strategic areas, all in alignment with our thematic and purpose-driven philosophy. We strengthened our market position and accelerated our wider societal ambitions. The combination with Exeter Property Group was completed, which positions EQT among the largest value-add real estate investment managers in the world. Furthermore, we continued to expand the palette of investment strategies, both within Private Capital

Intrum AB - Interim report April-June 2021

· Record cash collections and accelerated capital deployment with circa SEK 6 bn committed for 2021 · Landmark servicing transactions and gradual normalisation of new case inflows · Foreign exchange adjusted cash revenues growth of 17 per cent compared to Q2 2020 · ONE Intrum to accelerate in H2, all global front offices open and operationalFinancial results in brief, April-June 2021 (April-June 2020): · Adjusted EBIT increased to SEK 1,594 M (1,345) · Cash EBIT improved to SEK 1,413 M (1,294) · RTM cash EPS of SEK 26.22 (17.19) · RTM cash RoIC was 8.4 per cent (6.8)

Q2 2021 results: Strong performance in a recovery quarter

Zurich, Switzerland, July 22, 2021Ad hoc Announcement pursuant to Art. 53 Listing Rules of SIX Swiss Exchange· Orders $8.0 billion, +32%; comparable1 +24% · Revenues $7.4 billion, +21%; comparable +14% · Income from operations $1,094 million; margin 14.7% · Operational EBITA1 $1,113 million; margin1 15.0% · Basic EPS $0.37; +150%[2]  · Cash flow from operating activities and from operating activities continuing operations was $663 million  [][][][][][][][][]KEY FIGURES CHANGE CHANGE($ millions,

Norway Royal Salmon ASA evaluates strategic options

The board of directors of Norway Royal Salmon ASA (the "Board"; “NRS”) refers to NTS ASA's mandatory offer for all outstanding shares in NRS announced on 16 July 2021. The Board recommends the shareholders in NRS not to accept the offer. In the Board's view, the offer price does not reflect the underlying values in NRS. The Board has engaged Arctic Securities AS as financial advisor and Advokatfirmaet Wiersholm AS as legal advisor in connection with the offer. Together with its advisors the Board will explore alternatives for the company and its shareholders. Please also note that

InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod

July 21, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the Swedish Medical Products Agency (MPA) has given approval to start the phase III clinical study CONCLUDE in Sweden. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.“We are very pleased to have received approval from the MPA to start the phase III study CONCLUDE with cobitolimod, and we plan to initiate patient recruitment in Sweden and other countries after the summer,” said Peter Zerhouni, CEO of

Norway Royal Salmon ASA (NRS): Mandatory notification of trade

NTS ASA ("NTS") has on 21 July 2021 purchased through the market 20,420 shares in Norway Royal Salmon ASA ("NRS") at an average price of NOK 209 per share. No shares were purchased at a price higher than the offer price in the mandatory offer. Following completion of these transactions, NTS controls directly and indirectly through Midt-Norsk Havbruk AS 14,041,577 shares in NRS, equal to 32.23% of the total number of issued and outstanding shares in NRS. Held together with the 1,624,607 shares that NTS shall acquire from Gåsø Næringsutvikling AS, NTS will control 15,666,184 shares in NRS,

Director/PDMR Shareholding

21 July 2021 15:50 BST Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that on 21 July 2021, Marc Dunoyer, Chief Financial Officer, received 21,243 Ordinary Shares of $0.25 each in the Company (Ordinary Shares). The Ordinary Shares were issued to Mr Dunoyer on completion of the Company's acquisition of Alexion Pharmaceuticals, Inc. (Alexion) as part consideration for the 20,000 Alexion shares held by Mr Dunoyer at the time of completion. In accordance with the Agreement and Plan of Merger entered into by the Company on 12

Media invitation – Press conference on expansion investment Boliden Odda

Boliden has decided to invest EUR 700 m in Boliden Odda during the coming years. The intent is to increase annual production to 350 ktonnes and to produce by-products lead, gold and silver. At the press conference, Boliden’s President and CEO Mikael Staffas and General Manager at Boliden Odda Helene Seim will be available for media.   Date: 22 July. Time: 11.30 CET  The press conference is held in Swedish/Norwegian. To participate, please call 5 minutes before the opening of the conference:Link: https://boliden.videosync.fi/2021-07-22-pressmeeting_2021Tel:  · From Norway

There are no items matching the current filter
There are no more items matching the current filter
Back to top